CBD Market Provides ‘Enormous Incentive’ For FDA's Regulatory Answer But Decision Remains TBD
Executive Summary
FDA commissioner’s office representative Joseph Franklin explained, as other agency officials have previously, at FDLI confereice that determining whether to make lawful cannabinoids’ use in products other than drugs is both a priority and a challenge.
You may also be interested in...
‘Pharmaceutical’ Controls, Lower Costs: Future Of Cannabinoid Ingredients In Biosynthesis?
Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.
RWD Curtain Lifted On US Cannabinoids Information Gap, But Lawful Use Remains TBD
FDA gives directions on research needed for sufficiently robust “real world data” about non-drug products containing cannabinoids. While optimistic that real world data will help bridge information gap about the ingredients' safety, it’s also candid about the size of the gap.
US FDA Showed ‘Several’ Cards In CBD Bill Comments – CV Sciences’ Duffy MacKay
In itself, the proposed US Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 may be of little consequence. But the FDA’s October comments on the bill were revealing, CV Sciences’ Duffy MacKay says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: